DiscoverThe Bio ReportA BET on a Novel Approach to Treat Autoimmune Conditions
A BET on a Novel Approach to Treat Autoimmune Conditions

A BET on a Novel Approach to Treat Autoimmune Conditions

Update: 2024-10-30
Share

Description

The BET family of proteins regulates gene expression. Their overexpression has been implicated in both cancer and inflammatory diseases. Vyne Therapeutics is developing oral and topical BET inhibitors that treat inflammatory conditions ranging from rheumatoid arthritis to the skin condition vitiligo. We spoke to Vyne CEO David Domzalski and Vyne Chief Scientific Officer Iain Stuart, about the role BET plays in autoimmune diseases, its platform technology, and its efforts to develop BET inhibitors that are both potent and specific.

Comments 
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

A BET on a Novel Approach to Treat Autoimmune Conditions

A BET on a Novel Approach to Treat Autoimmune Conditions

Levine Media Group